Using Wearable and Mobile Data to Diagnose and Monitor Movement Disorders

NCT ID: NCT04231487

Last Updated: 2022-09-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

210 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-06-27

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the research is to better understand the motor behavior of individuals in health and disease. The specific purpose of this project is to identify if we can utilize a smartphone to diagnose different movement disorders and monitor their symptoms.

A. Objectives

1. Estimate symptom severity of Essential tremor (ET), Parkinson's disease (PD), Huntington's disease (HD), Primary focal dystonia (PFD), spinocerebellar ataxia (SCA), and Functional movement disorders (FMD) using a smartphone-based application
2. Differentiate individuals with the different movement disorders from healthy controls based on features from the smartphone data
3. Differentiate individuals with a specific movement disorder from people with other movement disorders based on features from the smartphone data

B. Hypotheses / Research Question(s) We hypothesize that we can estimate the severity of symptoms using a smartphone application and that, using those estimates, we can differentiate individuals with movement disorders from healthy controls and from people with other movement disorders.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Movement disorders are a group of neurological conditions that alter human movements. They lead to functional impairments, diminished quality of life, and significant societal, economic, and familial burden. Due to the increase in population and longer life expectancy \[1\], more and more people will have to live with movement disorders. However, access to movement disorder specialists is already limited and will get worse \[2\]. Therefore, there is an urgent need to develop tools to aid non-specialist medical professionals identify and manage the symptoms (both motor and non-motor) of those disorders such that specialist can focus on more severe and complex cases. While there are several conditions that can be classified as movement disorders, the current proposal will focus on six disorders that have overlapping symptoms and could prove difficult to differentiate for non-specialists and/or clinicians that do not readily have access to genetic testing or imaging facilities: Essential tremor (ET), Parkinson's disease (PD), Huntington's disease (HD), primary focal dystonia (PFD), spinocerebellar ataxia (SCA), and functional movement disorders (FMD). While trained movement disorder specialists may correctly identify each of these disorders and provide optimal treatment, general practitioners and clinicians living in rural areas that do not have access to the most up-to-date diagnostic tools, such as neuroimaging and genetic testing, may face difficulty when treating those patients due to symptom variability and overlap in symptom presentation between different disorders; leading to sub-optimal treatment outcomes. As such, the development of simple, accurate, and inexpensive tools to help guide their clinical decisions is warranted. The ubiquity of mobile technology and wearable sensors may enable the development of such a tool. In recent years, our group and others have used mobile phones and wearable technology to assess symptoms in a multitude of disorders. This highlights the feasibility of our proposed system for the assessment and monitoring of symptom severity in individuals with movement disorders.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Essential Tremor Parkinson Disease Huntington Disease Dystonia, Primary Spinocerebellar Ataxias Movement Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

ECOLOGIC_OR_COMMUNITY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Essential tremor

This is not an intervention study.

Specific to group: a) Diagnosis of ET, b) stable dose of medication for 30 days

No interventions assigned to this group

Parkinson's Disease

This is not an intervention study.

Specific to group: a) Diagnosis of PD, b) stable dose of medication for 30 days

No interventions assigned to this group

Huntington's Disease

This is not an intervention study.

Specific to group: a) Diagnosis of HD, b) stable dose of medication for 30 days

No interventions assigned to this group

Primary Focal Dystonia

This is not an intervention study.

Specific to group: a) Diagnosis of PFD, b) stable dose of medication for 30 days

No interventions assigned to this group

Spinocerebellar Ataxia

This is not an intervention study. Specific to group: a) Diagnosis of SCA, b) stable dose of medication for 30 days

No interventions assigned to this group

Functional Movement Disorder

This is not an intervention study. Specific to group: a) Diagnosis of FMD, b) stable dose of medication for 30 days

No interventions assigned to this group

Healthy Controls

This is not an intervention study.

People with Healthy Controls

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female
* At least 18 years of age
* Ambulatory
* English speaking
* Specific to group 1: a) Diagnosis of ET, b) stable dose of medication for 30 days
* Specific to group 3: a) Diagnosis of PD, b) stable dose of medication for 30 days
* Specific to group 4: a) Diagnosis of HD, b) stable dose of medication for 30 days
* Specific to group 5: a) Diagnosis of PFD, b) stable dose of medication for 30 days
* Specific to group 6: a) Diagnosis of SCA, b) stable dose of medication for 30 days
* Specific to group 7: a) Diagnosis of FMD, b) stable dose of medication for 30 days

Exclusion Criteria

* Serious untreated psychiatric illness that could impact the data collection
* Inability to understand task or protocol due to cognitive problems
* Other neurological condition that could affect the performance of motor tasks
* Musculoskeletal condition that could affect the performance of motor tasks
* Uncorrected vision impairment
* Specific to groups 1, 3, 4, 5, 6, and 7: Expected change in medication within the next 8 weeks
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rutgers, The State University of New Jersey

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jean-Francois Daneault, Ph.D.

Assistant Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rutgers University

Newark, New Jersey, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jean-François Daneault, PHd

Role: CONTACT

973-972-8482

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jean-François Daneault, PhD

Role: primary

973-972-8482

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Pro2018002015

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.